Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements
Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge
The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes
Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx
Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation
Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine
Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant